Medexus Pharmaceuticals Inc.

Total Valuation

Medexus Pharmaceuticals Inc. carries a market capitalization of 115.56M, placing it among publicly traded companies globally. Its enterprise value stands at 116.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Medexus Pharmaceuticals Inc. currently has 32.03M shares outstanding.

Valuation Ratios

Medexus Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 234.62. The price-to-sales ratio is 1.01, and the price-to-book ratio stands at 3.23.

Enterprise Valuation

On an enterprise value basis, Medexus Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 7.48 and an EV/FCF ratio of 2.95. The EV/Sales ratio of 1.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.96 provides insight into valuation relative to core operating earnings.

Financial Position

Medexus Pharmaceuticals Inc. maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 45.45, indicating elevated leverage, while an interest coverage ratio of 2.99 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Medexus Pharmaceuticals Inc. has paid 120,000.00 in income taxes, reflecting an effective tax rate of 98.16.

Stock Price Statistics

Medexus Pharmaceuticals Inc.'s stock has gained approximately 86.21939% over the past 52 weeks. The 50-day moving average sits at 3.09, while the 200-day moving average is 2.41.

Income Statement

Over the trailing twelve months, Medexus Pharmaceuticals Inc. generated 99.33M in revenue and converted that into -2.39M in net income, yielding earnings per share of -0.07. EBITDA reached 15.57M, while operating income came in at 5.84M.

Balance Sheet

Medexus Pharmaceuticals Inc. holds 6.52M in cash and equivalents against 22.26M in total debt, resulting in a net debt position of 15.74M. Total book value stands at 31.17M, with working capital of 10.20M providing operational flexibility.

Cash Flow

Medexus Pharmaceuticals Inc. produced 18.87M in operating cash flow over the past twelve months. After subtracting -15.15M in capital expenditures, free cash flow totaled 3.72M - equivalent to 0.12 per share.

Margins

Medexus Pharmaceuticals Inc. operates with a gross margin of 54.78, reflecting its pricing power and cost economics. The operating margin of 5.87 and net profit margin of -2.41 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Medexus Pharmaceuticals Inc.'s most recent stock split took place on January 7, 2019 with a 15:1 split ratio.

Scores

Medexus Pharmaceuticals Inc. posts an Altman Z-Score of 1.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.